Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen

Table 2

Comparison of continuous variables between baseline and month 3 in groups A and B. Note that the CNV area decreased significantly in group A () from baseline to month 3 and that BCVA improved in a statistically significant manner in group A from baseline to month 3 ().

	Continuous variables	Baseline	Month 1	Month 2	Month 3	Significance
Group A	CNV area (mm^2)	0.66 ± 0.84	0.49 ± 0.65	0.28 ± 0.42	0.23 ± 0.3
	BCVA (letters)	57.54 ± 20.52	57.14 ± 24.58	58.07 ± 26.05	64.15 ± 22.32
Group B	CNV area (mm^2)	0.94 ± 1.06	0.92 ± 0.99	0.96 ± 1.01	0.98 ± 1.00
	BCVA (letters)	64 ± 11.78	64 ± 17.67	56 ± 25.25	62.66 ± 26.36

Wilcoxon signed-rank test, value computed between baseline and month 3.